BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T054558
CREATED:20230126T191447Z
LAST-MODIFIED:20230126T191447Z
UID:36382-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Next Generation Cardiovascular Drug Development Summit
DESCRIPTION:Welcome to the Next Generation Cardiovascular Drug Development Summit \nExecuting Cell & Gene Therapy for Cardiac Regeneration \nFollowing technology advancements and the surge of investment in developing the next generation of cardiovascular disease drugs\, the opportunity to successfully leverage our knowledge of CRISPR/Cas9\, siRNA\, autologous iPSC therapy\, capsid engineering\, and digital medicine to reduce the soaring fatality rate has never been closer. \nThe Next Generation Cardiovascular Drug Development Summit in Boston is the only industry-led summit committed to overcoming preclinical challenges to advance your ischemic heart disease\, arrhythmogenic cardiomyopathy\, strokes and hypertension pipelines. \nTo know more visit: https://ter.li/s7qk9l
URL:https://www.pharmajournalist.com/event/next-generation-cardiovascular-drug-development-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T054558
CREATED:20230202T105002Z
LAST-MODIFIED:20230324T110700Z
UID:36448-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Cell Engager Summit
DESCRIPTION:The 5th Annual Cell Engager Summit is back in Boston\, MA this year – the only industry-led meeting bringing together 100+ pharma and biotech leaders will assemble for a 3-day agenda including 4 unique pre-conference workshops to delve into the biggest challenges cell engager therapeutics face. Breaking into the solid tumor\, preventing CRS and maximizing the quality of insights we gain from preclinical modeling. \nFor unmissable opportunities\, including: \n\nGain first-hand knowledge of the difficulties of developing kinase inhibitors to improve selectivity\, cross the blood-brain barrier\, and combat resistance\nUtilize cutting-edge platforms and technologies to maximise target validation and precisely predict off-target impacts to save time and costs\nEstablish long-lasting relationships by speaking with top pharma and biotech firms that are working on kinase inhibitor medicines and looking for the best-in-class solutions directly\n\nJoin your colleagues from the likes of Apexigen\, Regeneron Pharmaceuticals\, Genentech\, Roche\, Amgen\, Boehringer Ingelheim and many more at the most comprehensive cell engager event\, leaving no stone unturned\, this highly focussed meeting covers everything translational and clinical in greater depth and detail than any before it. \nDownload the full event guide for your sneak peek.
URL:https://www.pharmajournalist.com/event/5th-cell-engager-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T054558
CREATED:20230202T110212Z
LAST-MODIFIED:20230202T110212Z
UID:36461-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:5th Neuroimmunology Drug Development Summit
DESCRIPTION:With increasing prioritization for neuroscience discovery\, huge biopharma is investing in expanding its departments\, focusing on glial biology\, neuroinflammatory biomarkers\, and optimizing various approaches to target the likes of LRKK2\, TREM2\, and more. Therefore\, there is a great amount of novel and promising research to be discussed in 2023. \nUniting 100+ neuroinflammation and neuroimmunology experts across all neurological indications\, including AD\, PD\, ALS\, and MS\, the 5th Annual Neuroimmunology Drug Development meeting will return to Boston to host discovery\, preclinical\, translational\, and clinical experts from the likes of Genentech\, Muna Therapeutics\, Biogen\, Janssen\, Bristol Myers Squibb\, Sanofi\, Takeda\, and Roche. \nWith new speakers from the hottest biopharma in neuroimmunology delivering\, a comprehensive program of pioneering and cutting-edge content\, don’t miss your crucial chance to join this niche audience of innovators with a shared desire to explore strategy\, creation\, and implementation of research\, biomarker\, and clinical hypothesis testing in neuroimmunology. \nTo know more visit: https://ter.li/w642sd
URL:https://www.pharmajournalist.com/event/5th-neuroimmunology-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:Info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T054558
CREATED:20230207T094958Z
LAST-MODIFIED:20230207T094958Z
UID:36542-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:Gene Therapy Durability Summit
DESCRIPTION:Uniting the leading minds in gene therapy at the Gene Therapy Durability Summit\, join us to: \n\nLeverage knowledge from current clinical trials with relevant durability data across a range of indication types using AAV\nBetter understand what can be extrapolated and how to gain confidence in the data collected\nBuild study designs with durability in mind and explore how well preclinical models have predicted clinical durability to date\n\nHear from the likes of Pfizer\, Selecta Biosciences\, Spark Therapeutics\, Rocket Pharmaceuticals\, ASC Therapeutics and more across a preconference workshop day\, expert presentations\, interactive panel discussions\, dedicated Q&A time and highly appraised networking opportunities to meet and learn from the leaders of this pioneering field. \nWhen you attend you will: \n\nUnderstand the regulatory requirements to determine robust durability\nExplore the challenges short term immunogenicity has on durability\nNavigate how to overcome long term immunogenicity concerns on durability\nOptimize vectors constructs to maximize gene therapy durability\nDiscover how to better predict the translational success of durability when progressing from preclinical to clinical trials\n\nRegister to attend with your colleagues and get up to 20% off your tickets – https://ter.li/oeczu3
URL:https://www.pharmajournalist.com/event/gene-therapy-durability-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230425
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T054558
CREATED:20230227T130914Z
LAST-MODIFIED:20230227T130914Z
UID:36686-1682380800-1682639999@www.pharmajournalist.com
SUMMARY:2nd ADC Analytical Development Summit 2023
DESCRIPTION:The 2nd ADC Analytical Development Summit (April 25-27\, 2023 | Boston\, MA) is the only meeting focused on optimizing the application of analytical technologies for ADC\, from drug-linker and drug substance through to drug product to guide regulatory specifications and submissions\, to enhance understanding of your drug and to exert control over your process. \nSee the complete 2023 event guide here. \nWith many new ADCs under development\, the analytical challenges are only increasing as the existing hurdles keep changing\, with the regulatory guidance still being limited. This is a unique touch point for drug developers to discuss the core analytical challenges the industry is facing including drug linkers\, drug substances\, drug formulation\, and drug products. \nYou and your team can expect to leave this meeting equipped to have a deeper understanding of your drug and confidently enter conversations with regulators with thought-provoking insights from our expert speaker faculty including: \n\nYuan Gao\, Head of Analytical Development\, ADC Therapeutics \nJessica Webb\, Scientist\, Analytical Sciences\, AstraZeneca\nGuifeng Jiang\, Head of Analytical Development Pharmaceutical Operation\, Bolt Biotherapeutics\nThomas Gardinier\, Head of Materials Analysis\, Elucida Oncology\nSimon Letarte\, Director\, Gilead\nAdrienne Wildt\, Senior Director of Analytical Development\, ImmunoGen\nShuwen Sun\, Principal Scientist\, Merck & Co\nVimal Patel\, Vice President\, Head of CMC & Supply Chain\, Orum Therapeutics\nJulie Beaudet\, CMC Staff Scientist\, Regeneron Pharmaceuticals\nSarah Owen\, Senior Scientist Potency Assays\, Seagen\nMelvin Flores\, Director Quality Control Analytical & Microbiology\, Sutro Biopharma\nMay Zhu\, Director of Analytical Development- External Interface Management\, Takeda\n\nJoin them here. \nWith 100+ attendees\, 4+ hours of dedicated networking\, and 3 days of exciting new content\, including a pre-conference focus day on comparability studies\, this is a conversation you won’t want to miss to hopefully\, increase knowledge on your ADC quality attributes to understand and strive for regulatory approval
URL:https://www.pharmajournalist.com/event/2nd-adc-analytical-development-summit-2023/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230426
DTEND;VALUE=DATE:20230428
DTSTAMP:20260516T054558
CREATED:20230126T113838Z
LAST-MODIFIED:20230310T095341Z
UID:36359-1682467200-1682639999@www.pharmajournalist.com
SUMMARY:6th Annual Pharmaceutical Microbiology USA Conference
DESCRIPTION:6th Annual Pharmaceutical Microbiology USA Conference\nApril 26 – 27\, 2023 \nBoston\, MA\, USA \nhttp://www.pharma-microbiology-usa.com/PharmaJournalistWL \nSponsored by: LONZA \nChaired by: Donald Singer\, USP General Chapter Committee Microbiology Chair\, US Pharmacopeia  \nContamination Control and Microbial Methods Explored to Assure Product Quality and Prevention \nMicrobiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals\, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches. \nEnsuring the sterility of the finished product continues to be one of the most critical aspects of drug development\, however an array of factors is also sustaining new growth and transformation in this field. The regulatory landscape is changing\, firstly with the preparation of Annex I\, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination\, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms\, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement. \nOn top of this\, the developing integration of automation and robotics into the manufacturing pipeline\, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs\, are all highlighting the necessity of the field in Pharma. \nThis industry is ever expanding\, join our leading experts at the 6th Annual Pharmaceutical Microbiology East Coast Conference in Boston\, USA to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with the  industry professionals\, discuss revisions in regulatory and guidance documents\, and gain a deeper insights. \nEvent Hashtag: #MicrobiologyUSA  \nKey Conference Highlights: \n\nReview implementation guidance and validation for efficient microbial testing programs\nUncover how to implement effective contamination control for manufacturing and the impact throughout pharmaceutical microbiology\nLearn how to control mold contamination and apply risk-based tools to tackle recovery\nDelve into the role the microbiologist plays in bioburden assessments and holistic closure integrity testing for new drug modalities\nUnderstand innovative techniques to control contamination as it relates to cell therapy products\, combination\, and traditional microbiological drug products\n\nView the full agenda: http://www.pharma-microbiology-usa.com/PharmaJournalistWL
URL:https://www.pharmajournalist.com/event/6th-annual-pharmaceutical-microbiology-usa-conference/
LOCATION:Boston\, MA\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:lamprini.balasi@saemediagroup.com
END:VEVENT
END:VCALENDAR